» Articles » PMID: 32492688

Prior Therapeutic Experiences, Not Expectation Ratings, Predict Placebo Effects: An Experimental Study in Chronic Pain and Healthy Participants

Overview
Publisher Karger
Specialties Pharmacology
Psychiatry
Date 2020 Jun 4
PMID 32492688
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Many clinical trials fail because of placebo responses. Prior therapeutic experiences and patients' expectations may affect the capacity to respond to placebos in chronic disorders.

Objective: The scope of this study in 763 chronic orofacial pain and healthy study participants was to compare the magnitude and prevalence of placebo effects and determine the putative role of prior therapeutic experiences vs. expectations.

Methods: We tested placebo propensity in a laboratory setting by using 2 distinct levels of individually tailored painful stimulations (high pain and low pain) to reinforce expectations and provide a hypoalgesic experience (conditioning phase). Afterwards, both levels of pain were surreptitiously set at a moderate pain level to test for placebo effects (testing phase). Pain and expectation ratings were assessed as primary outcomes using visual analog scales.

Results: In both chronic pain and healthy participants, placebo effects were similar in magnitude, with the larger prevalence of responders in the healthy participants. Although chronic pain participants reported higher pain relief expectations, expectations did not account for the occurrence of placebo effects. Rather, prior experience via conditioning strength mediated placebo effects in both pain and healthy participants.

Conclusions: These findings indicate that participants with chronic pain conditions display robust placebo effects that are not mediated by expectations but are instead directly linked to prior therapeutic experiences. This confirms the importance of assessing the therapeutic history while raising questions about the utility of expectation ratings. Future research is needed to enhance prediction of responses to placebos, which will ultimately improve clinical trial designs.

Citing Articles

What should constitute a control condition in psychedelic drug trials?.

Colloca L, Fava M Nat Ment Health. 2025; 2(10):1152-1160.

PMID: 39781538 PMC: 11709123. DOI: 10.1038/s44220-024-00321-2.


Understanding Placebo and Nocebo Responses Based on a Randomized Sham-Controlled Study on Acupuncture in Integrative Cancer Care.

Efverman A Integr Cancer Ther. 2024; 23():15347354241300068.

PMID: 39548800 PMC: 11569494. DOI: 10.1177/15347354241300068.


The Power of a Good Word: Enhancing the Efficacy of Analgesics in Clinical Settings.

Treister R, Cohen V, Issa L, Beiruti Wiegler K, Izakson A, Agostinho M Psychother Psychosom. 2024; 94(1):60-67.

PMID: 39496250 PMC: 11797921. DOI: 10.1159/000541810.


Uncertainty of treatment efficacy moderates placebo effects on reinforcement learning.

Augustat N, Endres D, Mueller E Sci Rep. 2024; 14(1):14421.

PMID: 38909105 PMC: 11193823. DOI: 10.1038/s41598-024-64240-z.


Placebo and nocebo effects of percutaneous needle electrolysis and dry-needling: an intra and inter-treatment sessions analysis of a three-arm randomized double-blinded controlled trial in patients with patellar tendinopathy.

Domenech-Garcia V, Pecos-Martin D, Blasco-Abadia J, Bellosta-Lopez P, Lopez-Royo M Front Med (Lausanne). 2024; 11:1381515.

PMID: 38903823 PMC: 11187289. DOI: 10.3389/fmed.2024.1381515.


References
1.
Hashmi J, Baria A, Baliki M, Huang L, Schnitzer T, Apkarian V . Brain networks predicting placebo analgesia in a clinical trial for chronic back pain. Pain. 2012; 153(12):2393-2402. PMC: 3494789. DOI: 10.1016/j.pain.2012.08.008. View

2.
Colloca L . Placebo, nocebo, and learning mechanisms. Handb Exp Pharmacol. 2014; 225:17-35. DOI: 10.1007/978-3-662-44519-8_2. View

3.
Ohrbach R, Markiewicz M, McCall Jr W . Waking-state oral parafunctional behaviors: specificity and validity as assessed by electromyography. Eur J Oral Sci. 2008; 116(5):438-44. DOI: 10.1111/j.1600-0722.2008.00560.x. View

4.
Kam-Hansen S, Jakubowski M, Kelley J, Kirsch I, Hoaglin D, Kaptchuk T . Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014; 6(218):218ra5. PMC: 4005597. DOI: 10.1126/scitranslmed.3006175. View

5.
Carvalho C, Caetano J, Cunha L, Rebouta P, Kaptchuk T, Kirsch I . Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain. 2016; 157(12):2766-2772. PMC: 5113234. DOI: 10.1097/j.pain.0000000000000700. View